Reset Therapeutics, Inc.

Centessa Pharmaceuticals (UK) Limited

Synchronicity Pharma, Inc.

Synchronicity

Paul Humphries

Ross Bersot

Roderick Alan Porter

Bruce Lefker

Wojciech Zawodny

Sarah Bucknell

Karl Gibson

Matthew Spendiff

The present disclosure relates to compounds of Formula (I′): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin receptor activity and may be used in the treatment of disorders in which orexin receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or a complication in emergence from anaesthesia.

Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R, R, R, R, R, R, R, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD. 

Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R, R, R, R, R, R, R, A, B, C', D, E, F, G, H&#x2032;, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma. 

Carbazole-containing sulfonamides as cryptochrome modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R, R, R, R, R, R, R, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma. 

Growing community of inventors

Santa Clara, CA, United States of America

Paul Humphries